BioTime Announces Passing Of Director Abraham E. Cohen

BioTime, Inc. (NYSE MKT: BTX) announced with sadness that Abraham (Barry) E. Cohen, a member of its Board of Directors, passed away on Thursday, November 22, 2012 at the age of 76.

Mr. Cohen has been a valued member of the Board of Directors and was a member of several committees, including the Audit Committee. Mr. Cohen had a long career in the pharmaceutical industry, where he played a key role in the development of international business for Merck & Co. While at Merck, Mr. Cohen was a leader in the development of Merck’s international business, initially in Asia, then in Europe and, subsequently, in all international regions as President of Merck Sharp & Dohme, which manufactures and markets human health products outside the United States.

“It was a great privilege to work with a man of Barry’s stature,” said Michael D. West, CEO of BioTime. “His enthusiasm and energy for the industry was infectious. We will continue to labor to advance his vision of a brighter future for mankind through advances in medical research.”

Copyright Business Wire 2010

If you liked this article you might like

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

5 Hated Stocks Poised to Turn Around on Earnings

Insider Trading Alert - TIPT, BTX And WASH Traded By Insiders

Insider Trading Alert - ASYS, BTX And STAG Traded By Insiders

Commit To Purchase BioTime At $2.50, Earn 14.5% Annualized Using Options